vs
Side-by-side financial comparison of Marygold Companies, Inc. (MGLD) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Marygold Companies, Inc. is the larger business by last-quarter revenue ($7.6M vs $5.5M, roughly 1.4× Taysha Gene Therapies, Inc.). Marygold Companies, Inc. runs the higher net margin — -7.5% vs -507.8%, a 500.2% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs -4.5%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs -1.5%).
Marygold Companies, Inc. is a U.S.-headquartered diversified holding company that operates across three core segments: financial services, specialty manufacturing, and consumer goods. It primarily caters to North American markets, driving long-term value growth via strategic investment in, and operational optimization of, its portfolio of subsidiary entities.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
MGLD vs TSHA — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.6M | $5.5M |
| Net Profit | $-576.0K | $-27.9M |
| Gross Margin | 74.0% | — |
| Operating Margin | -8.3% | -516.0% |
| Net Margin | -7.5% | -507.8% |
| Revenue YoY | -4.5% | 171.3% |
| Net Profit YoY | 67.0% | -48.3% |
| EPS (diluted) | $-0.01 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.6M | $5.5M | ||
| Q3 25 | $7.0M | $0 | ||
| Q2 25 | $7.2M | $2.0M | ||
| Q1 25 | $7.0M | $2.3M | ||
| Q4 24 | $8.0M | $2.0M | ||
| Q3 24 | $7.9M | $1.8M | ||
| Q2 24 | $8.3M | $1.1M | ||
| Q1 24 | $7.9M | $3.4M |
| Q4 25 | $-576.0K | $-27.9M | ||
| Q3 25 | $-356.0K | $-32.7M | ||
| Q2 25 | $-1.5M | $-26.9M | ||
| Q1 25 | $-1.0M | $-21.5M | ||
| Q4 24 | $-1.7M | $-18.8M | ||
| Q3 24 | $-1.6M | $-25.5M | ||
| Q2 24 | $-1.9M | $-20.9M | ||
| Q1 24 | $-529.0K | $-24.1M |
| Q4 25 | 74.0% | — | ||
| Q3 25 | 77.0% | — | ||
| Q2 25 | 67.8% | — | ||
| Q1 25 | 75.0% | — | ||
| Q4 24 | 74.1% | — | ||
| Q3 24 | 73.1% | — | ||
| Q2 24 | 72.5% | — | ||
| Q1 24 | 70.5% | — |
| Q4 25 | -8.3% | -516.0% | ||
| Q3 25 | -18.2% | — | ||
| Q2 25 | -16.5% | -1347.1% | ||
| Q1 25 | -21.4% | -930.5% | ||
| Q4 24 | -22.8% | -985.8% | ||
| Q3 24 | -27.4% | -1448.4% | ||
| Q2 24 | -33.3% | -1915.4% | ||
| Q1 24 | -18.7% | -713.3% |
| Q4 25 | -7.5% | -507.8% | ||
| Q3 25 | -5.1% | — | ||
| Q2 25 | -20.4% | -1353.6% | ||
| Q1 25 | -14.4% | -935.2% | ||
| Q4 24 | -21.8% | -929.0% | ||
| Q3 24 | -20.1% | -1427.5% | ||
| Q2 24 | -22.5% | -1882.0% | ||
| Q1 24 | -6.7% | -705.4% |
| Q4 25 | $-0.01 | $-0.08 | ||
| Q3 25 | $-0.01 | $-0.09 | ||
| Q2 25 | $-0.04 | $-0.09 | ||
| Q1 25 | $-0.02 | $-0.08 | ||
| Q4 24 | $-0.04 | $-0.07 | ||
| Q3 24 | $-0.04 | $-0.10 | ||
| Q2 24 | $-0.05 | $-0.09 | ||
| Q1 24 | $-0.01 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.6M | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $22.7M | $246.9M |
| Total Assets | $27.8M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.6M | $319.8M | ||
| Q3 25 | $12.5M | $297.3M | ||
| Q2 25 | $12.8M | $312.8M | ||
| Q1 25 | $15.6M | $116.6M | ||
| Q4 24 | $14.9M | $139.0M | ||
| Q3 24 | $17.5M | $157.7M | ||
| Q2 24 | $15.0M | $172.7M | ||
| Q1 24 | $16.1M | $124.0M |
| Q4 25 | $22.7M | $246.9M | ||
| Q3 25 | $22.9M | $219.0M | ||
| Q2 25 | $23.0M | $248.7M | ||
| Q1 25 | $24.3M | $55.1M | ||
| Q4 24 | $23.4M | $71.5M | ||
| Q3 24 | $25.5M | $88.8M | ||
| Q2 24 | $26.6M | $108.9M | ||
| Q1 24 | $28.4M | $53.8M |
| Q4 25 | $27.8M | $343.3M | ||
| Q3 25 | $28.4M | $316.6M | ||
| Q2 25 | $30.4M | $333.3M | ||
| Q1 25 | $33.5M | $138.4M | ||
| Q4 24 | $33.0M | $160.4M | ||
| Q3 24 | $35.9M | $180.2M | ||
| Q2 24 | $32.9M | $200.4M | ||
| Q1 24 | $33.7M | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-908.0K | $-26.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-908.0K | $-26.7M | ||
| Q3 25 | $-533.0K | $-24.2M | ||
| Q2 25 | $-3.3M | $-20.2M | ||
| Q1 25 | $-1.2M | $-22.0M | ||
| Q4 24 | $-770.0K | $-18.3M | ||
| Q3 24 | $-893.0K | $-21.6M | ||
| Q2 24 | $-1.9M | $-21.5M | ||
| Q1 24 | $-658.0K | $-19.8M |
| Q4 25 | — | — | ||
| Q3 25 | $-562.0K | $-24.3M | ||
| Q2 25 | $-3.4M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-776.0K | $-18.3M | ||
| Q3 24 | $-940.0K | $-21.6M | ||
| Q2 24 | $-2.0M | $-21.7M | ||
| Q1 24 | — | $-19.9M |
| Q4 25 | — | — | ||
| Q3 25 | -8.1% | — | ||
| Q2 25 | -46.8% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -9.7% | -905.5% | ||
| Q3 24 | -11.9% | -1210.9% | ||
| Q2 24 | -23.8% | -1951.9% | ||
| Q1 24 | — | -584.5% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | 0.7% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.1% | 0.1% | ||
| Q3 24 | 0.6% | 2.0% | ||
| Q2 24 | 0.7% | 18.1% | ||
| Q1 24 | 0.0% | 4.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MGLD
| Fund Management Related Party | $4.6M | 60% |
| Food Products | $1.7M | 22% |
| Beauty Products | $1.2M | 15% |
| Other | $268.0K | 4% |
TSHA
Segment breakdown not available.
